31 – 40 of 45
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.
(
- Contribution to journal › Article
- 2014
-
Mark
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013
(
- Contribution to journal › Scientific review
-
Mark
Risk of HIV transmission from patients on antiretroviral therapy: A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naive HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial
(
- Contribution to journal › Article
- 2012
-
Mark
Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load
(
- Contribution to journal › Article
-
Mark
Low Prevalence of Transmitted Drug Resistance in Patients Newly Diagnosed with HIV-1 Infection in Sweden 2003-2010
(
- Contribution to journal › Article
- 2011
-
Mark
Bilirubin-A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy
(
- Contribution to journal › Article
-
Mark
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naive HIV-1 infected patients
(
- Contribution to journal › Article
-
Mark
Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010
(
- Contribution to journal › Scientific review
- 2010
-
Mark
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-na
- Contribution to journal › Article